RxDoctor Payments DataLook up a doctor →

Rachel Presti, MD

Infectious Disease · Saint Louis, MONPI 1770596389

Payments from drug & device makers

$2,650,824in general payments, 2019–2025

Across 499 payments — averaging $5312.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$2M
  • Janssen Research & Development, LLC$294K
  • Viiv Healthcare Company$152K
  • GSK$131K
  • Gilead$63K
  • Merck$9K
  • plus $98 from 2 others
$1,545in research payments, 2019–2025

Across 11 payments — averaging $140.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Viiv Healthcare Company$2K

What the payments were for

  • Consulting fees$6,96074%
  • Travel & lodging$1,47616%
  • Food & beverage$92110%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.380$2,002,363
Janssen Research & Development, LLC25$294,145
Viiv Healthcare Company28$151,725
GSK16$130,809
Gilead33$62,842
Merck14$8,842
Amgen2$71
Janssen Scientific Affairs, LLC1$26

How this compares

$2,650,824 in reported general payments places this provider in the 95th percentile of 177 infectious disease providers in Missouri.

See all infectious disease providers in Missouri

Medicare billing

Part B allowed, 2024
$9,638
Medicare patients
43
Services billed
127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala41$159,370
TivicayDolutegravir Sodium30$82,258
Albuterol Sulfate HfaAlbuterol Sulfate12$494
Atorvastatin Calcium17$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$62,842$159,37041 claims
Viiv Healthcare CompanyTivicay$151,725$82,25830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 infectious disease providers in Missouri.

Other infectious disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →